Oxford BioDynamics Plc announced that it has entered into a collaboration with Holos Life Sciences Pte. Ltd. to develop non-invasive epigenetic biomarkers associated with sports-related concussions. The collaboration will leverage OBD's EpiSwitch™ platform to help determine and monitor systemic epigenetic changes and potential physiological reprogramming due to sports-related concussion. Based on pre- and post-concussion monitoring, biomarkers will be identified and evaluated to assist in the determination of changes in an individual's epigenetic profiles, in response to a concussive event. EpiSwitch™ stratification will provide new insights and help to quantify the risk of prolonged effects of sports-related concussion, and potentially improve recovery and rehabilitation. Under the terms of the collaboration agreement, Holos will supply the participants' blood samples, with OBD providing its proprietary EpiSwitch™ platform and methodology for the development, evaluation, and validation of epigenetic biomarkers. Biomarker readouts will be based on minimally invasive blood testing. The analysis aims to identify a signature of EpiSwitch™ biomarkers to evaluate the impact of sports-related concussive events on individuals. Informative EpiSwitch™ biomarkers potentially could be monitored in relation to concussive events to inform return-to-play protocols and determine when athletes can resume activities.